IDH1 and central nervous system cancer: In addition, we analyzed the expression of HOXD-AS2 in different progression status, subtypes and IDH mutation status in the Chinese Glioma Genome Atlas (CGGA) cohort [31] (Figure S1a–c), finding no significant differences.